Illinois Health and Science, a nonprofit health care system based in Decatur, acquired IBA Molecular last week.
And while terms of the sale were not disclosed the sale includes all of IBAM NA's cyclotron sites and its research and development facilities. IBA Molecular is jointly owned by SK Capital Partners and Ion Beam Applications S.A. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs.
"We are excited to announce the closing of the sale of IBAM NA to IHS. I would like to personally thank all of IBAM NA's employees for their commitment, dedication and hard work," Renaud Dehareng, CEO of IBA Molecular, said. "The future for IBAM NA is bright under IHS' ownership given their leadership in nuclear medicine and strong commitment to customers, employees and patients."
Illinois Health specializes in enhancing patient care by making strategic investments in health care related opportunities, while IBA Molecular is a leading developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging with operations throughout Europe and Asia.
Rothschild Inc. served as exclusive financial advisor to IBA Molecular for the transaction.